Silexion Therapeutics Business Summary

Silexion Therapeutics Corp (SLXN) is a clinical-stage biotechnology company that operates on a pre-revenue business model, primarily focused on the discovery and development of RNA interference (RNAi) therapies for KRAS-driven cancers. The company’s revenue strategy is centered on future licensing agreements, milestone payments, and potential commercialization of its proprietary LODER (Local Drug EluteR) delivery platform. Its primary business segments are categorized by its therapeutic pipeline, led by SIL204, a second-generation siRNA candidate targeting KRAS mutations (G12D, G12V, and Q61H) in solid tumors such as locally advanced pancreatic cancer (LAPC), colorectal, and non-small cell lung cancer. Silexion competes directly with established RNAi and oncology firms such as Alnylam Pharmaceuticals, Avidity Biosciences, PanTher Therapeutics, and Neuphoria Therapeutics, positioning itself as a specialized player in the localized delivery of gene-silencing therapeutics for previously "undruggable" oncogenic targets. The leadership team is headed by Chairman and CEO Ilan Hadar, who brings significant pharmaceutical pedigree from his former roles as Country Manager and CFO at Foamix Pharmaceuticals (now VYNE) and Finance Director at Pfizer Israel. The technical and scientific direction is led by Dr. Mitchell Shirvan, Chief Scientific and Development Officer, whose 30-year career includes senior leadership at Teva Pharmaceuticals and Macrocure. The company was co-founded by Dr. Amotz Shemi and Prof. Eithan Galun, with Mirit Horenshtein-Hadar serving as the Executive Vice President of Finance. Silexion’s board and investor base feature notable industry figures, including Ilan Levin, the company’s largest individual shareholder, and Ruth Alon, alongside institutional backing from Moringa Sponsor LP and the Guangzhou Sino-Israel Biotech Fund.